Hypercoagulable state and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with beta-thalassemia major in Kuwait

Acta Haematol. 2010;123(1):37-42. doi: 10.1159/000260069. Epub 2009 Nov 21.

Abstract

Introduction: Patients with thalassemia major often present with a hypercoagulable state, the pathogenesis of which is still not understood.

Materials and methods: This study evaluates the risk factors for hypercoagulability in 50 beta-thalassemia major patients and 50 healthy controls. Fasting total homocysteine, protein C (PC), protein S (PS), antithrombin (AT), activated protein C resistance (APCR) and lupus anticoagulant (LA) were assessed. MTHFR C677T mutation was determined.

Results: Significant reductions in PC, PS and AT were noted in patients. Only 4% of the patients had hyperhomocysteinemia. Thirty-two percent of the patients were heterozygous and 4% were homozygous for MTHFR C677T mutation.

Conclusion: The natural coagulation inhibitors PC, PS and AT were significantly reduced in patients with beta-thalassemia major and were thus important risk factors for the hypercoagulable state, but hyperhomocysteinemia and MTHFR mutation do not seem to be significant risk factors for thromboembolic events.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activated Protein C Resistance / blood
  • Adolescent
  • Adult
  • Antithrombins / metabolism
  • Base Sequence
  • Blood Coagulation Disorders / blood*
  • Blood Coagulation Disorders / etiology*
  • Blood Coagulation Disorders / genetics
  • Case-Control Studies
  • DNA Primers / genetics
  • Female
  • Heterozygote
  • Homocysteine / blood
  • Homozygote
  • Humans
  • Kuwait
  • Lupus Coagulation Inhibitor / blood
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Point Mutation*
  • Protein C / metabolism
  • Protein S / metabolism
  • Risk Factors
  • Thromboembolism / blood
  • Thromboembolism / etiology
  • Thromboembolism / genetics
  • Young Adult
  • beta-Thalassemia / blood*
  • beta-Thalassemia / complications
  • beta-Thalassemia / genetics*

Substances

  • Antithrombins
  • DNA Primers
  • Lupus Coagulation Inhibitor
  • Protein C
  • Protein S
  • Homocysteine
  • Methylenetetrahydrofolate Reductase (NADPH2)